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Abstract: Traditionally man has looked to nature to provide cures for diseases. This approach still exists today in the form of 
‘bio-prospecting’ for therapeutically-active compounds in venoms. For example, the venoms of many reptiles offer a spectacular labo-
ratory of bioactive molecules, including peptides and proteins. In the last 10–15 years, there have been a number of major proteomic and 
genomic research breakthroughs on lizard venoms. In this current review, the key findings from these proteomic and genomic studies 
will be critically discussed and suggestions will be offered for future focused investigations. It is our intention that this article will not 
only provide a comprehensive picture of the state of current knowledge of the components of lizard venoms, but also engender aware-
ness in readers of the need to protect and conserve such uniquely precious natural resources for several reasons, including the potential 
benefit of humankind.
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Introduction
The study of biologically-active molecules, including 
peptides and proteins, present in tissues of invertebrates 
and vertebrates, has been a core research focus in the 
life and health sciences for many years. Such study has 
produced many important leads in drug discovery.1,2 
It is likely that such peptides and proteins represent an 
ancient form of intra- and intercellular communication. 
Scientists have designed peptide/protein phylogenetic 
trees by translating common amino acid sequences to 
ancestors of peptides/proteins found to be present in 
both invertebrates and vertebrates.3,4 For example, some 
of the mammalian gastroenteropancreatic (GEP) pep-
tides and the vasoactive intestinal peptide (VIP) from 
humans are also present in the central and peripheral 
nervous system of lower vertebrates.5 These findings 
indicate that the vertebrate hormones/active peptides 
may have originated in neural tissues before different 
vertebrate evolutionary lines developed.3
The last review of lizard venom research was pub-
lished in 1996 by Raufman.4 Since then there have been 
several major research breakthroughs and reports on 
lizard venom components and evolution in this inter-
vening period. These include 1) the development of a 
minimally invasive and reliable technique for acquiring 
lizard venoms,6 2) the development of robust molecu-
lar techniques for constructing cDNA libraries to obtain 
proteomic and genomic data from lyophilised lizard 
venom secretions,7,8 3) the discovery of venom toxins in 
two additional lizard lineages (varanids and iguania),9 
4) the discovery of novel bradykinin-receptor inhibitory 
peptides (helokinestatins) in helodermatid (Heloderma 
suspectum and Heloderma horridum) venoms, and 5) the 
discovery of natriuretic peptide toxins in both heloder-
matid (H. suspectum and H. horridum) and a varanid 
(Varanus varius) venom.10,11 In addition, a recent study 
has also demonstrated that Komodo dragons (Varanus 
komodoensis) and the extinct giant Megalania (Varanus 
prisca) possess(ed) venomous bites.12 In the present 
review, all the recent proteomic and genomic research 
on lizard venoms will be discussed and suggestions for 
future investigations will be offered.
Development of a Technique  
for Acquiring Lizard Venoms
Kwok and Ivanyi developed a minimally-invasive 
technique for venom extraction from lizards,6 and 
genomic and proteomic studies on these venoms 
have been published by Chen et al and Kwok et al 
objectively supporting that this method of obtaining 
lizard venom worked extremely well.7,10,13 Kwok and 
Ivanyi’s technique offered a rubber-covered object 
for the lizard to bite. After the lizard was safely 
restrained,14 had opened its mouth and the oral cavity 
had been rinsed with water or saline, they presented 
it with a plastic-reinforced rubber squeeze bulb. As 
soon as the bulb contacted the lizard’s mouth, it would 
voluntarily bite down on the bulb. Care was taken to 
ensure that the posterior teeth (toward the angle of the 
jaw) engaged the bulb. Then the lizard was held with 
its head at a 30°–45° angle (below horizontal) and its 
mouth was suspended above a glass or plastic vessel.6 
After a lizard bit the rubber bulb and compressed and 
released its jaws several times, drops of venom would 
be produced and the venom would drop into the vessel 
from along the gums of the lower jaw.
The advantages of this modified technique are that 
it is generally non-injurious to the lizard, reduces ani-
mal stress and the shedding of blood from breaking 
teeth that might be inadvertently collected using other 
methods.15 It also maximizes the quantity of venom 
that can be safely collected. Overall, the technique 
appears safe and reliable for use in venom extrac-
tion from lizards, which is of great benefit when 
research requires investigations into the venoms of 
rare/protected species, and provides a robust source 
of valuable lizard venoms for biomedical researchers 
performing intensive proteomic and genomic research 
for potential drug discovery.
Development of Molecular Techniques 
for constructing Lizard Venom cDnA 
Libraries
The emerging science of functional genomics 
integrates data derived from proteomics, genom-
ics, and physiomics to provide a holistic view of the 
life process—a necessary prerequisite for a global 
understanding. In the case of lizard venom pro-
teomics, where many toxic proteins are of relatively 
high molecular mass, direct sequencing to obtain 
full primary structure is the method of choice. Many 
researchers resort to molecular cloning to this end 
using either degenerate primers designed for small 
sequence tags derived from the protein of interest or 
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those designed for conserved nucleic acid domains of 
related molecules from other species. In 2002, Chen 
et al first reported the simple and rapid technique that 
unmasks venom protein mRNAs present in lyophi-
lized lizard venom samples.7 The traditional approach 
to isolation of mRNA from lyophilized venom sam-
ples fails to recover appropriate RT-PCR-compatible 
mRNA and, hence, its absence was assumed.5,7 How-
ever, Chen and his co-workers developed a novel 
methodology wherein they used magnetized oligo-dT 
DynaBeads for polyadenylated mRNA capture and 
circumvention of precipitation, recovering venom 
protein poly(A) mRNA, which is RT-PCR compat-
ible and representative of all the studied classes of 
proteins from reptile venoms.7 These findings imply 
that the apparent absence and/or lability of mRNA in 
complex biological matrices is not always real and 
pave the way for accelerated acquisition of molecular 
genetic data on venom toxins for scientific and poten-
tial therapeutic purposes without sacrificing ani-
mals. By using the principle of this robust technique, 
Kwok et al have further demonstrated that parallel 
proteome and venom gland transcriptome analyses 
can be performed on such samples.8 They reported 
the presence of DNA that facilitates the more widely 
used applications of gene sequencing, such as molec-
ular phylogenetics, in a non-invasive manner that 
does not require specimen sacrifice. From this “sur-
rogate” tissue, they successfully acquired partial 12S 
and 16S rRNA gene sequences that were presented for 
illustration purposes. Thus, from a single sample of 
lizard venom, robust and complementary proteome, 
transcriptome and genome data can be generated for 
applications in diverse scientific disciplines.
Discovery of Additional Venomous 
Lizards
Until recently, it was believed that only one lineage of 
extant lizards, the helodermatids (represented by two 
species H. suspectum and H. horridum), had evolved a 
venom delivery system.9,16 In 2005, Fry and his interna-
tional coworkers made a major scientific breakthrough 
in lizard venom history by investigating the evolution 
of venomous function in squamates. They obtained 
sequence data from five nuclear protein-coding genes 
representing major squamate lineages. Phylogenetic 
analyses showed that the closest relatives of venomous 
snakes are anguimorph (which includes helodermatids) 
and iguanian lizards (Fig. 1).9 In a further investigation, 
they reported the presence of venom toxins (Table 1) in 
two additional lizard lineages (varanids and iguania), 
and through Magnetic Resonance Imaging (MRI), 
showed that all lineages possessing toxin-secreting 
oral glands form a clade.9,11,17
The venom toxins in varanids and iguania exhibit 
considerable sequence diversity, which is consistent 
with the birth-and-death mode of protein evolution 
that has given rise to a wide diversity of bioactivi-
ties in reptile venoms. These molecules represent a 
tremendous relatively unexplored resource, which is 
valuable to drug design and development, as well as 
aiding our understanding of reptile evolution.9,18
Following these discoveries Fry et al described the 
immediate effects of bites from these lizards as mild 
envenomations. Bites on human digits by a lace mon-
itor (Varanus varius), a Komodo dragon (V. komo-
doensis), and a spotted tree monitor (V. scalaris), all 
produced similar effects: rapid swelling, localized 
disruption of blood clotting, and shooting pains up 
to the elbow, with some symptoms lasting for several 
hours.9 Recently, Fry and his co-workers published 
further evidence demonstrating that the Komodo 
dragon possesses a venomous bite.12 MRI scans of a 
preserved skull showed the presence of two venom 
glands in the lower jaw, and found that it secreted 
venom containing several different toxic proteins 
(Table 1). The known functions of these proteins 
include inhibition of blood clotting, lowering of blood 
pressure, muscle paralysis, and the induction of hypo-
thermia, leading to shock and loss of consciousness 
in envenomated prey.12 Moreover, Fry et al further 
analysed the structure and mechanics of the Komodo 
dragon’s skull and jaw muscles. It was discovered 
that the bite force of the Komodo dragon is not par-
ticularly strong.12 Rather than inflicting devastat-
ing bites, the jaws are best suited for clamping on to 
prey and resisting it from pulling away, giving time 
for the venom to penetrate the wound.12 This means 
that less effort is required to subdue its victim, and 
allows larger animals to be preyed upon. As a result 
of these findings, the previous theory that bacteria 
were responsible for the deaths of Komodo dragon 
prey could be disputed.12 In the same study, Fry et al 
also hypothesised that the Komodo dragon’s extinct 
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and even larger relative, Megalania (V. prisca), may 
have used the same method of prey capture, since this 
lizard also had a strong skull but relatively slender 
jawbones.12 It was very closely related to the Komodo 
dragon and the lace monitor, both of which have now 
been proven to be venomous. Fry et al had previously 
shown that the capacity to produce venom evolved 
once in the common ancestor of snakes and lizard 
groups like the iguanas and monitors.9 There is every 
reason to believe that Megalania used venom as well, 
which would make it the largest venomous animal to 
have ever lived.
Discovery of Helokinestatin  
and natriuretic peptides
The venom of helodermatid lizards has been studied 
as far back as 1967,19,20 but only recently has much 
of the biochemistry been elucidated. Over the last 
decade, the level of research into helodermatid 
venom components has intensified; particularly that 
directed towards the discovery of novel bioactive 
agents. The therapeutically useful exendin peptide 
toxin (marketed as ByettaTM), isolated from helo-
dermatid venoms for the treatment of diabetes, is 
the most remarkable example of lizard venom-drug 
discovery.21
According to Russell’s report in 1983, approxi-
mately 90%–95% of freeze-dried helodermatid 
venoms consist of proteinacious material made up of 
non-toxic proteins, toxins, enzymes and peptides.22 
Kwok and his co-workers believed that a large num-
ber of novel proteins/bioactive peptides within the 
venoms remained to be discovered. But, due to a lack 
of contemporary focus on the study of such venoms, 
this had not been determined. In 2007, Kwok et al 
reported a novel bradykinin-receptor inhibitory pep-
tide from helodermatid venom named helokinestatin.10 
 Helokinestatin represents an entirely novel structural 
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Figure 1.
Source from Fry et al.9
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class of helodermatid venom peptide displaying a 
unique bradykinin-receptor inhibitory activity. The 
discovery of helokinestatin in venoms of heloderma-
tids represents an additional novel factor acting on 
the kinin/kininogen system—at the level of selective 
bradykinin inhibition.10 Recently, Fry et al investi-
gated novel venom proteins produced by differential 
domain-expression strategies in helodermatid lizards. 
Multidisciplinary techniques were used to investigate 
the structure, function and evolutionary diversifica-
tion of the unique venom system in these enigmatic 
lizards.11 In their study, for the first time more protein 
types (e.g. natriuretic peptide) were reported from 
Heloderma venoms.11 They also isolated additional 
isoforms of previously characterised Heloderma 
toxins belonging to the CRISP, exendin, helokines-
tatin, kallikrein and phospholipase A2 (PLA2) groups 
(Table 1).11
The findings of Kwok’s and Fry’s studies, combined 
with the information available from the literature,23 
reveal how little we still know about the toxinology of 
the enigmatic Heloderma lizards. With respect to their 
venoms, we do not know enough of their composition, 
role of individual venom components in prey capture, 
or in vitro activities relative to subsequent physiolog-
ical sequelae following envenomation.
summary, conclusions and Directions 
for Further Investigations
In summary, there have been a number of major sci-
entific breakthroughs in lizard venom research over 
the last decade. To begin with, the development of a 
minimally invasive technique for acquiring samples 
of lizard venoms, along with robust molecular tech-
niques, help provide a consistent and reliable source 
of valuable lyophilized lizard venoms for intensive 
proteomic and genomic research studies.6,7,8,10,13 
Secondly, two additional lizard lineages, monitors—
including the Komodo dragon—and the iguania, 
were confirmed as possessing toxin-secreting oral 
glands and venom toxins.9,12 As a result of these dis-
coveries and reports, new insights into the evolution 
of the venom system in squamate reptiles have been 
provided and new avenues have been opened for bio-
medical investigations into the bioactive profiles of 
novel components establishing a path of new leads 
for drug design and development.
Thirdly, Raufman’s 1996 review article reported 
five bioactive peptides that had been isolated from 
the venom of Heloderma lizards.5 Additionally, four 
novel helokinstatin toxin variants have been discov-
ered in helodermatid venoms.10,11 These peptides 
possessed a potent bradykinin receptor inhibitory 
activity and represent a prototype of a novel struc-
tural class of helodermatid venom peptide.10 Thus, 
they represent additional and novel factors acting on 
the kinin/kininogen system—at the level of selective 
bradykinin inhibition. In addition, more protein types 
(e.g. natriuretic peptide), previously reported only 
from snake venoms, were for the first time identified 
in Heloderma venoms.11,22,24 The natriuretic peptide 
transcript from the helodermatids also encoded tan-
dem repeats of functional helokinestatin peptides, 
revealing that a single gene expresses both toxin 
types, with post-translational processing liberating 
the different peptides.11 These newly identified venom 
toxins from lizards may herald a new era of research 
Table 1. Lizard venom proteins and characterised 
activities.
Toxin type Toxic bioactivity References
Helokinestatin-1, 
-2, -3, -4
Bradykinin-inhibition 10,11
exendin-1, -2,  
-3, -4
Induction of  
hypotension mediated  
by relaxation of  
cardiac smooth muscle
11,13
Kallikrein Release of bradykinin 
from kininogen
10,11,17
Lethal Toxin 1 Lethal inhibition of  
direct electrical 
stimulation
11
Natriuretic  
peptides
Potent induction of 
hypotension leading to 
loss of consciousness; 
mediated through the 
binding of GC-A  
resulting in the  
relaxation of cardiac 
smooth muscle
11
PLA2 Platelet inhibition 
mediated By  
epinephrine-induced 
pathway
11
Three finger  
toxin like peptide 
(3LP-1)
Unknown 
 
11 
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focus in proteomics and genomics of lizard venoms 
and their use for drug discovery.
This review shows how little we know about the 
fundamental evolution and function of these unique 
natural bioweapon systems and molecules, or the 
molecular evolution and function of the associated 
peptides/toxins. Therefore, it would be beneficial 
for future investigations in lizard venom research to 
focus on these proteomic and genomic techniques, 
which have cast a new light on our understanding of 
the history of the venom system among lizards. It is 
obvious that lizard venoms possess a high potential 
for drug discovery, as evidenced by the commercial 
success of the drug ByettaTM, which is used to treat 
human diabetes and is derived from a helodermatid 
exendin-4 toxin. Results from venom research over 
the last decade suggest that further studies and sam-
pling from well-known or newly-identified venomous 
lizards are likely to recover novel isoforms of types 
already identified, as well as discovering entirely new 
classes of bioactive peptides/toxins. These peptides/
toxins have great potential for use against a wide 
variety of pharmacological targets in humans, such as 
the treatment of pain, diabetes, multiple sclerosis and 
cardiovascular diseases, making them an invaluable 
source of ligands for studying the properties of these 
targets in different experimental paradigms for drug 
development.
The foremost clinical disadvantage to venom 
 peptide/protein drugs such as ByettaTM is that they 
cannot ordinarily be administered via the oral route 
because they are likely to be either degraded by 
peptidase enzymes in the gastro-intestinal tract, 
or be too large to be absorbed. As a consequence, 
these drugs are typically delivered via the paren-
teral route, which makes the therapy intrusive for 
the patient and increases the costs for the health-
care provider. The intravenously administered 
peptidomimetic glycoprotein IIb/IIIa inhibitor, 
tirofiban (AggrastatTM), which was based upon com-
pounds derived from Malayan pit viper (Callose-
lasma rhodostoma) venom is a fine case in point.25 
The transdermal, nasal, buccal/sublingual and pul-
monary routes have all shown potential as means of 
peptide/protein drug delivery. Although ExuberaTM, 
Pfizer’s insulin inhalation device, was launched 
and subsequently withdrawn from the market, there 
are several promising transdermal peptide/protein 
delivery systems which have recently been launched 
or are currently undergoing clinical trials.26 As such, 
it seems that the search for potential lead compounds 
from lizard venom will need to proceed in tandem 
with research into formulation development to ensure 
that pharmacological discoveries are translated into 
commercially successful therapies.
We hope this review stimulates further interest into 
this dynamic field and we would also like to empha-
size that, in the last 10 years, many reports suggest 
that many reptiles are experiencing dramatic range 
reductions and are threatened with extinction.27–30 
Loss of biodiversity will result in the loss of impor-
tant proteomic and genomic information that these 
animals contain, along with potentially unknown and 
untapped sources of new pharmacologically active 
agents. Therefore, in addition to stimulating further 
research in reptile venoms, we hope that this article 
serves to raise people’s awareness regarding the 
value of these animals, and fosters a sense of respon-
sibility to protect and conserve these precious natural 
resources.
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